Downloaded from journal.bums.ac.ir at 11:03 IRDT on Tuesday May 1st #./ "S M6

Transcription

1 1387 "#$% 4 15! ( ) $% &'# " ('"# ( ) *+,! - %& '( -!" # - -#./ -#!, & '() %& * +) %& $!"# : $!"# 8.,9 +!1..) +01 * %- 203/ 45& /.. <=.# - % >- :$ ; '& 6) + E.)+!# % >- :$ ; + D ( E >>3/ -?@/ +!1 - : L!, 4. 5 & '& 56 +) E. IJ K / 1375 :.# LST U +) O <J PQ I.. RN$ ( E. <"/ 4. - %."N/ M;6J () M E &Z"# E--..- U"/ 4- +!, $J Y + VNW/ 4'& VNW/ 4+ " - X/ 4+ " - U3 4-J..$J K U>3/ +6=/ - P0/05 -! [1 - t Chi-Square & & SPSS & 6J< E-?$ E. $ -. J.- (%79/9) ) (%47) : E- + D '& - $W : J $W P + D % >- :$ ; ". $W.- + M E L!, - 4. J $W U) : 4M E L!, J $W 4< + D 5 4. / J $W :. & b 45 / J $W P -.- <) -& + D & %50/7 +). - M;6J () 4%."N/ " '& %73/1.- Squamous Cell Carcinoma (SCC) J $W 4%53/5 :>/ <) 5 - $W %30/7 c <// d" I- :/ () : - %21 75 : - %2/3) - g6j h.$ : 10 T -. L!, J.. - E-- ef$ - +. /.(84 $?S -f$k -S"$# [1 4 " -.!/ 4R- Ui 1 US 4P ". J + +#/ : 6( " $ % - efn P %T Oj 2K- [3@ <= # 6+ d"..,. - :$ ; EO$- I$!"# I. I5 I IQ(- I$ : (1387 "#$% *4 *15 ) 1387/6/13 : /5/19 : /12/6 :,-..# 6 <>S EOW - 46 E.W - '& & E W - I:k( E.( '& gn -(Y), < %$" - 0T % -.# :*-& haghighifa@yahoo.com : $ ( :" :?>/ 2.# 6 <>S EOW - - L003/ 6) os $ E.W - ">S Ln os 3 "S M6 1 75

2 " B DDE F- #G... "% <?#@ #: AB=:5> #<,; :.(1). %T - O- wk 5 / $! 4"9 < 300/000 + M-6 + q. % >/ EO$- + E.3$ Lq - $ 20/000 $)$(.(1) - <= < ~/ E.-= {S U- P % - %T $! "9 P %T *. %."N/ :$)) 4+ 4%$( <) : - 4(ACS) & %T "= "N/ 4P # <)..# E.3$ Lq >S + t #- <) 50/000 g +" US (1) +$- -# " 4(# ) -.!/ 4 - (#!J Y x E-?$ 4L - 8f 4O>9 L!Jg0 %& -...?S US 4- >#.(6). - 4%T +01 (# Z/ - -# /?/ M;. I. y Y %T Y I. %& " 4%)-) - " $! :i %S + M$> " %q(6 - (ALL * ) -9 M$?.(3) (AML ) -9 zi I. E.- $W P# M - %T o! (7) %- $W.@ % - %$( %T I. - $W Y e JÄ# +01 M - v W) 9 - %T q Y. US I(3) % 6 +v- K U9 + I. - 6( wn/ %T - JÄ# +01!"# - %T s>$n Y +) 3 $!"# +!1 - d" I. L?$ s>$n +). VNW u/ - O- * Acute Lymphocytic Leukemia (ALL) Acute Myelocytic Leukemia (AML) #!K U- + % >- :$ ; EO$- - p1 +>"# US ( + %& -X +$( + W Lq$ ( " 4$?S. - r. 5 +>"# os +.(1) - +) - "! st U 'u 4 :> t U/ 4i/ ->"S - :$ %& -.(2) - / -= :> -Sj i/ M % +? M - - j W) + q.(2). %T v- - "S T -? + : -? 465/ & W) - %T + : -? 804/3-6.@ -= >S - $W -.(3) %? 6.@ 4 UO 4 * E.W VNW / $ ; Lq$ 4" - % +$ Y o! >S %S + %.(2). E. E.uw %T (;.) +!1 - %. 4%/ ## %$" ; /- 6) - %T %- - 4 %T $J x - % - + %T % 4? $( 4 $! '// + 9 %- 4%$( %T.(4). E. 56 %T 4>/ EO$- ". 4j & 2uT.(5). - UW/ % - ". yu) %12/7 % >/ EO$- ". $! $. & <) P efn % & ". <"/ %7 zu0/ :k( E-6J %& %6 4 JW O({ 4$. & <) >@ 1 US.(1) - -%- -% nw %;$! - K US -f$k 4S"$#!, M$ ; 4-}. 76

3 1387 "#$% SPSS + + D J $W 4 - E (%79/9) ) -J (%47) : y E- 5 + %$u - y O.- L!, 450/84±16/75. 44/87±10/94 () %" - 36/23±14/41 M E y O.- : 33/14±11/5 %."N/ M;6J $W -! T +. %".(P<0/001) - L!,. 5 J g6j +. $ T - Tg D J $") +) 3 + I-- %W (%14/5) 1384 : + D J $W (%5/7).- 41 :.# J Z/ $W 4+!, $J Y x. E. E-- %W + D '// + + " -.!/ $").- (%2/3). (%66/9) 5 D '// + +!, - U3 $") $W - %32/3.- (%24/3) P (%43/3) %."N/ + + " - ". % D 6 4%1/7 '// + %."N/ P 49 E.-.- %2 %3/8 $") $W } &) (%72/3) < + D '// + J 49. / Y (1 :.#) (%0/1) J I- (%75) <) -& + D J $W 4(%12/5) <)) + D '// + - (TCC) ) U :W6 / (%6/3) <) <v + - 4P # %T CIN * L!,.(8). - $! '// + $? +!1 4203/ <= % / +) + +#/ :$ ; EO$- M;. US +!1 4- E.W <= # % %$ - % >- :$ ; M;. 8.,9 L6 * 1385 / 1375 : % >-.. <= $'& 0, 12 -# E. <"/ >>3/ -?@/ +!1 - EOW& - U.# '& 6) -, < %$" EOW&? 009 / 1375 : 4.# 6 <>S EOW - + +$( (Y) >- :$ ; 4 & '& +=$ +) RN$ 4- E. 56 (. 45) %..$J K VNW/ 4+ " - X/ 4 + D LST U3 4'& VNW/ 4+ " - U =W - ~/ +!, $J Y E. +/ x " + +) O <J - E.-5& M;6J () + D -..- uw 4- U P Tg L!, 4%."N/..$J K " -.!/ %- - " E- - %$u Z/ x + 4?@/ gn - 2>1 J Z/ :.# 4 U3 y s>$n Y +(0 x + >>3/ gn - u( s>$n E- - $ s>$n 2T - O +(0 Chi-Square & %& 4 P0/05 -! [1 - U0$( t & %& E-?$ - & 6J< )Å + <q.. E-?$ Transitional Cell Carcinoma (TCC) * Cervical Intraepithelial Neoplasi 77

4 " B DDE F- #G... "% <?#@ #: AB=:5> #<,; : (%6/1) uj -& () (%42/7) -& () + (%41/3) -& () + D - +0 I- % -.- (%9/9) 5.{$. & / (%95/1) c <// 4."N/ :> / (%1) Yolk Sac )) J $W.- E-- ef$ - + J $") %."N/ + -(# ÇT / J Z/ - - J $W +) -- %W / '(9 + D 6 J $") (%75) GCT + D. E- (%12) JGCT Y * %."N/ :>/ <) % + D '// + J $") $W 4/ 6 - %21/4 I- (%14/3).{$. & (%64/3).- <) + D %2-1. L!, J 4: 60 y E- - 4 g6j.- %17/1 : 60 q y E ) 3 + I-- %W g6j ". u( J - %2 $") ~$ T + 4: 60 y E - Y %17/1 4: 60 q - -J - %3/9) ". u( J d" I(P<0/001) - (%5 U0 - %14/1) Tg L!, (%2 U0 -! T + ) + u( $ ).(P<0/001) - $W M?/ + %$ - ) %" J Z/ E. E-- %W 42 :.# - U3 (%20/1)? VNW U3 +) - D J $W.. - ) +0 $ ) J $") (%80/ ).# +.(2 :.#) - (%0/7 4-16) %- %$ + D Y * 9. / J Z/ x - (%75) <) -& + D J $W 4/.(1 :.#) J Z/ x d" I- (%6/3) / + D J $W 4%."N/..(1 :.#) - (%26/9) M/$$ 9 Tg L!, J $") $W (%74/7) U) : + D '// + +!, Y '(9 Y d" I- (%0/9).. Q $W 4/.+0uT '(9 4%."N/ - (%61/7) 31 :>/ / + D J.(1 :.#) $W 4P 5 $W (%98/8) :. & b + D J L!,.- (%75) SCC * + D ". J '// + J $") $W P Tg Q(- (%80/4) * $ + D.{Q + D 6 - %10/9.- (%8/5) * 4%."N/ M;6J () %.- Q () %> J $W (%50/7) :/ () %42/4 - I-- ef$ - + J $") (%4) E- () 6 - %6/4 - J () - 4%."N/ 5 / %.- E. 56 c <// + D '// + J $") $W.- (%0/3) JGCT BSST (%30/7) %."N/. J Z/ x $W (%34/6) <) 4/ Y * (%3/9) Yolk Sac / )) J $W.- E-- ef$ - + J $") :>/ / + D '// + J $").- (%2/02) M/$$ / (%61/7) 31 %."N/ 31 :>/ / J x D '// + J $") $W 4/ Y * * Squamous Cell Carcinoma (SCC) Benign Sclorosing Strumal Tumor (BSST) Juvenile Granolosa Cell Tumor (JGCT) 78

5 1387 "#$% :;< 0*12 3.# %- +W % K %.u *-J PuT Z"# 3,4 - $W 4+!1 U@9 h$ * E- - PQ 4(%47) : y E- - '& E $") I. E. W ( ) : y I(%4/9). - : 60 q y E- - %" +#/. +).$( 1 4E - x $ % - efn E - + 4O {S - - & [1 %-q 5& d" I, $. U{( 1 US UK.9 %O %- fnw/ 4$. L.K.. x + <q E (%79/9) ) 4%" -.!/ $W - $ -. J.. - $ + $ - Tg L!, L!, %T J - 8$ I- U- +. / $ 2T - Tg + D $ % - x ' Oj <.S +) O- US I. 2T - O J U{( 6) + $- <.S 4. U / -f$k [1 %- OW& - 4$. M ZJ +) $ - S"$#.. x +, US %66/9 '& - $W,9 +!1 - () %& P I- 5 + D Tg L!, %24/3 %."N/ M;6J K.! E- - %2/3. (%6/5)..$- :$ ; ". $W +) -- %W +!1 h$ %& P %."N/ PQ 4P + D % >- - E. <= L!1 h$ +$J I. $. & j & 8 -- N" W) U- :$ ; - Z %T 4E.<= L!1 2uT I $% &'( ) * * +*, -* -1!.) )& * * +* ( !/) /4 574 < 0/4 3 < -& 0/3 2 < -& 0/1 1 } &) 26/9 213 $. & b (- 345 :-.!/) %."N/ 61/ :>/ / 29/9 103 :> / 2/3 8 + (# ÇT / 4/1 14 :>/ <) 2/02 7 M/$$ / (- 26 :-.!/) %."N/. 11/5 3 c <// 3/8 1 ) ) 3/8 1 Yolk Sac / 34/6 9 <) 11/5 3 <) 7/7 2.{$. & <) 26/9 7 M/$$ / (- 6 :-.!/) <) -& 6/3 1 <) 12/5 2 <)) 6/3 1 (TCC) ) U :W6 / 0* , -* -2.) 80/9 0/7 2/3 2/3 7/7 2/3 1/3 1 1/4 100, ! 79

6 " B DDE F- #G... "% <?#@ #: AB=:5> #<,; :.. Borde Line $J Y É3 '& <"/ 4203/ h$ * M;6J () + D & $W 4%."N/ %24/8 5 I- (%73/1) 2uT.. -- UW/ - %2. -."N/ L!, M;/ Y +) +!1 + D (%38) & $W 6. <= 6u/ %$.(9). 56 M;6J () 4%."N/ M;6J () 4+!1-2uT I- J $W %50/7 :/ () () 6 -&< - %."N/ / +v.(13). 56 M$ j E-/ $! :/ / 4,9 +!1 h$ * c <// + D J $W 4%."N/ 5 -# Z# +$J I- -& () %& P + v - I(1041) -- N" $! -& () 4-&< - %."N/ E-/ +!1 M - I(13). 56 %."N/ 5 / %$( - %."N/ / E.9# " 226 +) / 4. <= 1999 / () + D (%31/1).@- $W 45.(14) - (%28/9) c <// %& P.{$. & 4%."N/. /,9 +!1 - / J $W %53/5 >/ <) - <) -- ef$ - +. I(%36/6) - J $W - >/ <) :k( >/ <) 4E. <= W } 2uT -.( ) %."N/ ". <"/ % &< - %."N/ E-/ E.<= %."N/. / $! 4<) -& ( 226 +) +!1 M - d" I(13). 56 %T 4. <= %$( - %."N/ / E.9# ". P %."N/ 4$. & '// + % >- :$ ; " ) +!1 M - (1) %T 4. <= %/ ## %$" - % >- %4/85 %."N/ %T 4". - %12/2 P - d" I(4). 56 %2/54 9 %T %T E -J - % ; g" :$ ; %T $! 4$. & PQ %."N/ 4P,9 +!1 h$ +) (9). <S % - >- >S "= 4%."N/ %T 6 & - I-- N" + % t %47 US % - %T :u - + t (11410) %T >S +) $J - +=$ + 4,9 203/ - '& - yu). 4 g6j : 20 y E- - +) L@ + I. g6j 60 q %2/1 : %1 4: %1/8 $ :"$9 '// + I- -# ". %17/1 : Z# +). g6j g6j. L!, +.( ) -- N" -# %13 45 %86/1 49 '&.. -. %1/7 M E L!, $. & Q L. +#- + 4<) JW 1 :/& Q +) +$( M E +!, J $W.(10) - ". 8T + %20 56 I- %72/2 < 49 5 / 5 / $! %S + < +) E. %$.? $! %$Q - E. J! 9.(1041) 9. / J $W 4g } - U) : d" I- (%75) <) -& + D + 9 M E L!, J $W %7/74 Endolymphatic - M d" I-- ef$ - <) +u M +) - -# Stromal Myosis 80

7 1387 "#$% 4 15 $ # % - +) P %T %74/9 * d" I(1041) - E.- : 45 y M <) Y 4;$ Oj 4- ) - +!1 $u % - -.!/ +$u I(17) +$J g ).(18). E. %- /- ZK" +!# :$ ; J 4203/ h$ * + I- g6j T - >- + D %14/ : + D %5/9 +) 3 J : 10 T - O- LuS + I : : - I E. $W h.$. L!, YK + ". % %2/3 - % (# <. ". Y I +$ : / Plovidiv 1996 : - (- 100/000 ) - 58/ (19) -- %W g6j L!, %74/7 U) : 4,9 +!1 - d" ( K +) -- ef$ M E %15-10 U) L!, )Å + <q I q )) + U.u/ %3-2 # : + U.u/ 20 UuK )) : d" I. % g6j O 40 P O +$u I. nw >uk U) : )) *(9 ( -" + )) - q O>9 %6 I(20410) -- &g %6 %- q I L?$ ( - s>$n 2T +ÖÄ/ US + Z# o! - q O>9 -- L!1 I E. E-- u( -f$k -S"$# 8f +). E-- %W 4E.3$ Lq $. -= 1 g6j " /)) Öj ; O>9 %6 +) 0T - I. E" q O>9 I(21) Z ( 6 A $ -u") 4q q US 4,9 +!1 - : J %-q ". $! %83/4 %."N/ :>/.(14) 4P '&,9 - % D %84/1 - d" I- M E L!, %11/7. <"/ 4 - E.<= "Ñ 4s? Ç$ 45) P '& (%38).@- $W (. Tg 4.. ) 4-6 %6 I. - E-- ef$ (13) %2 Tg 4L!, L!, J $W 4,9 +!1 h$ * *& Q(- + D 4P M E - %80/4-6 * $ - (%8/5) "Ñ +h - I.- E. W %$" - E.<=. 56 Q(- %33 $ %17/64 "Ñ d" I-. N",9 +!1 +=$ +) (13) - '>j - 4* $ Y )Å + <q HPV * wn/ 3/ M;6J!uT. M MQ/& LÄ/ >@ US +) - -= > LÄ/ +> < CIN +).$(. Y I(16415) P %T Y UuK * -& x * $ -J q " ( Y efn) HPV %-.# 4ZK" VNW/ I - #/ UK T + P %T. /.(10)." OW J $W :. & b, ef$ - + P 5 L!, I- %75 SCC 4. / J $W (%98/8) US 4?O :> <) 4E. <= L!1 2uT * Human Papilloma Virus (HPV)

8 " B DDE F- #G... "% <?#@ #: AB=:5> #<,; : +!# % ). - ($ ) % + & LST % N 4>J T ZK" +!# E. -.W {S U{( -. +# ) " " % - EOW - & LW$ <$3 *)."3 %$" '& EOW& <$3 %)) d".-- -.K W/.# (Y), < +). U-. / -f$k -S"$# +ÖÄ/..u>T + - $W % 5 ( -W / +$J * :-- %T - - efn s>$n 1 US P VNW/ # :; ; " $J.# k( % P %T *- :64& 1- Scott JR, Gibbs RS, Karlan BY, Haney AF. Danforth's Obstetrics and Gynecology. USA: William & Wilkins; Anderson G, Simonton OC. Cancer: 50 Essential Things to Do. USA: Saunders; Frei H. Cancer Medicine. USA: BC Decker; Mortazavi SH, Alidoosti A, Shahrad B, Shahidi M, Raoufi M, Norouzi A, et al. Epidemiological study of cases of registered cancers at department of radiation oncology Jorjani Hospital. J Med Council Islamic Republic Iran. 2003; 4 (20): Shahrad B, Mortazavi M, Aminian Sh Survey 1698 female genital malignancies in Jorjani Hospital Pejouhandeh Quarterly Res J. 2002; 28 (7): Fallahian M, Hashemi F, Zahabiun A, Hoseinali Pour SM. Survey on Epidemiological Factors of Patients of Precancerous and Cancerous Lesions of Cervix in the Years in the Hospitals of the Shahid Beheshti University of Medical Sciences, and Iran University of Medical Sciences. Teb Va Tazkiey J. 2000; 36: Weiss JR, Moysich KB, Swede H. Epidemiology of Male Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 2005; 14: Gharabaghi Sh. Determination of percentage of neoplastic lesions of uterine cervix by age, age of marriage, number of parity & educational level in Tabriz. Med J Tabriz Univ Med Sci Health Services. 1998; 38 (32): Iran Scientific Association of Woman's Cancer. Abstract Book of First Congress of Iran Scientific Association of Woman's Cancer. 1 st ed. Tehran: Tehran University of Medical Sciences Montag A. Kumar V. The female genital system and breast. In: Kumar V, Abbas AK, Fausto N, Mitchell R. Robbins Basic Pathology. 8 th ed. USA: Saunders; Kadkhoayan S, Ghaffarzadehgan K. Correlation of p53 protein expression and clinicopathologic features in ovarian epithelial tumors. IJBMS. 2004; 7 (1): Amant F, Moerman P, Neven P, Timmerman D, VanLimbergen E. Endometerial Cancer. Lancet. 2005; 366: Iran Pathology Association. Abstract Book of Iran Pathology Congress. 1 st ed. Tehran: Iran Pathology Association; Nowak M, Szpakowski M, Malinowski A. Ovarian tumors in the reproductive age. Science Direct Ginekologia Polska. 2002; 73 (4): Berek JS. Berek and Novak's Gynecology. Translated by: Ghazijahani B, Zonozi A, Bahrami N. Tehrna: Golban:

9 1387 "#$% Rosai C, Ackermas D. Surgical pathology. 9 th ed. St. Louis: Mosby; Duarte-Franco E, Franco EL. Cancer of the Uterine Cervix. BMC Woman Health. 2004; 25 (4): 1:S Chaturvedi AK, Engels EA, Gibert ES, Chen BE, Stom H, Lynch CF, et al. Second cancers among survivors of cervical cancer: evaluation of long-term risk. JNCI J National Cancer Institute. 2007; 99 (21): Nikolova Z, Ananoshtev N, Karnolski I. Female sex organs malignancies incidence in Plovdiv district for he period Science Direct Folia Medica. 1993; 40 (38): Vassilato U, Papakonstantino U, Graps A, Kondi-Paphit I, Hasiako S. Primary gestational choricarcinoma of the uterine cervix. Report of case and review of the literature. Int J Gynecol Cancer. 2007; 17(4): Hacker NF, Moore J. Essentials of Obstetrics and Gynecology. Translated by: Malek Mohammadi S, Arian Mehr S. 4 th ed. Tehran: Tabib;

10 " B DDE F- #G... "% <?#@ #: AB=:5> #<,; : Title: The epidemiologic study of the neoplasms in the internal genital system of women referring to pathologic centers in Birjand ( ). Authors: F. Haghighi 1, S.A. Saadatjoo 2, F. Fanoodi 3, M. Taherian 3 Abstract: Background and Aim: One of the first steps in diagnosing neoplasms is their epidemiological study. Being aware of the epidemiological condition of different kinds of neoplasms can help us a lot in educational planning and research; and cure the disorder as necessitated in a certain area. The present study was done to epidemiologically investigate the neoplasms in woman s internal genital system in Birjand between 1996 and Materials and Methods: This analytical and descriptive study was done on 2979 biopsy dossiers of the internal genital system of women who had referred to Birjand pathology labs between 1996 and The dossiers whose pathological reports were benign and malignant neoplasms, preneoplasic damages, and ovary physiologic cyst were selected from the biopsy dossiers. Then a check-list, which demanded demography information, sampling place and time, pathological diagnosis, primary diagnosis, and the damaging process, was filled out. Finally, the obtained data was analysed by means of SPSS software using Chi-Square and t- test at the significant level of PN0.05. Results: Most Pathologic cases were found in patients aged between 40 and 59 years (47%). Most of the patients (79.9%) who were studied were urbanites. The number of the cases of the malignant neoplasma in rural areas was twice that of urban areas, and the number of the cases of preneoplasic damages in villages was three-fold. The most malignancy rate of women s internal genital was that of the cervix. In uterus, most cases of benign neoplasms were leiomyoma, and most cases of preneoplasic damages were complete moles and the majority of the cases of malignant neoplasms included adenocarcinoma. But the most cases of benign preneoplasic tumors were endocervical polyps. The most number of malignant tumors were Squamous Cell carcinoma (SCC). Out of ovary pathogenecity, 73.1% were physiologic cysts from which 50.7% were luteal ones. In addition, adult teratoma, as the most percentage of benign neoplasms, amounted to 30.7% and epithelial carcinoma, as the most percentage of malignant tumor, reached 53.5%. Thus, it was found that the frequency of malignant cases gradually increased during this period of 10 years (from 2.3% in 1996 to 21% in 2006). Conclusion: Regarding the high frequency of cervical malignancies, studying risk factors such as marital age, number of pregnancies, socioeconomical status, and infections are very necessary. Moreover, planning to do right and accurate screening of women especially in rural areas is of critical importance. Key Words: Metaplasia; Dysplasia; Neoplasm; Benign; Malignant; Epidemiology; Genitalia 1 Corresponding Author; Associate Professor, Department of Pathology, Faculty of Medicine, Birjand University of Medical Sciences. Birjand, Iran. haghighifa@yahoo.com 2 Instructor, Faculty of Nursing and Midwifery and Member of Diabetes Research Centre, Birjand University of Medical Sciences, Birjand, Iran. 3 Physician 84